Fractyl Health Calls Tranche A Warrants

An announcement from Fractyl Health, Inc. ( (GUTS) ) is now available.

On December 15, 2025, Fractyl Health announced the call of its Tranche A Common Stock Purchase Warrants, initially issued during its August 2025 public offering. The company achieved the necessary clinical and trading milestones, allowing warrant holders to exercise their options at $1.05 per share until December 30, 2025. If all warrants are exercised, Fractyl could gain approximately $17.9 million in gross proceeds, which would bolster its financial position as it progresses with its clinical programs.

The most recent analyst rating on (GUTS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.

Spark’s Take on GUTS Stock

According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.

Fractyl Health’s overall stock score is primarily impacted by its precarious financial situation, characterized by high leverage and ongoing losses. However, strong technical indicators and positive clinical developments provide some optimism. The company’s strategic progress in clinical trials and a solid cash position offer potential upside, but financial risks remain significant.

To see Spark’s full report on GUTS stock, click here.

More about Fractyl Health, Inc.

Fractyl Health, Inc. is a metabolic therapeutics company based in Burlington, MA, focused on developing innovative treatments for metabolic diseases such as obesity and type 2 diabetes. The company aims to shift treatment from chronic symptomatic management to durable, disease-modifying therapies targeting the root causes of these conditions. Fractyl holds a substantial intellectual property portfolio with numerous patents and applications in the U.S. and abroad.

Average Trading Volume: 4,146,735

Technical Sentiment Signal: Buy

Current Market Cap: $307M

Find detailed analytics on GUTS stock on TipRanks’ Stock Analysis page.